Payment & Shipping Terms:
|Product Name:||Orlistat||CAS NO:||96829-58-2|
|Molecular Formula:||C29H53NO5||Molecular Weight:||495.73|
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). In the United States and the European Union, orlistat is available for sale without a prescription. Generic formulations of orlistat are available in some countries.
Usage and Dosage
1. An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent.
3. Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
4. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
5. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
6. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
|T3 /Liothyronine sodium/Cytomel||CAS 55-06-1|
|Lorcaserin HCI||CAS 846589-98-8|
|CLA (Conjugated Linoleic Acid)||CAS 2420-56-6|
|Calcium Pyruvate||CAS 52009-14-0|
|Dextromethorphan Hydrobromide||CAS 6700-34-1|
|Lorcaserin hydrochloride||CAS 846589-98-8|